Direct Cellular Oximetry for Monitoring Patient Health

Company

History of Opticyte

 

Next-generation oximetry: Allows clinicians real-time monitoring of cellular oxygenation and perfusion. Early detection and intervention for shock improves patient outcomes and reduces healthcare costs in ICUs, ORs, and EDs.

 

The CellSat™ oximetry technology has been refined in the Schenkman Laboratory at the University of Washington.  With $3.0M in non-dilutive funding from the NIH, Coulter Foundation, WA Life Sciences Discovery Fund, NIH STTR Phase I, SBIR Phase II, CoMotion Innovation, and Medic One, the technology has made significant strides toward de-risking the measurement of myoglobin oxygenation in superficial skeletal muscle and the use of that measurement in the emergency department.

 

Opticyte incorporated in May 2016 prior to signing the exclusive license agreement. Cofounders include Robert V. Masterson, CEO, and serial entrepreneur including past CEO of Prevention and Onconome (Tessera Diagnostics); Kenneth A. Schenkman, MD, PhD, and critical care physician at Seattle Children’s Hospital, Lorilee Arakaki, PhD, UW research scientist in optical spectroscopy, and Wayne Ciesielski, UW research scientist.

 

 

Opticyte, Inc.

University of Washington

Box 352141

4000 Mason Road, Suite 300

Seattle, WA 98195

Phone: +1.206.775.5525

bob@opticyte.com

Copyright © 2019 Opticyte. All rights reserved.